Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma

Taku Kikuchi, Takehiko Mori, Yuya Koda, Sumiko Kohashi, Jun Kato, Takaaki Toyama, Tomonori Nakazato, Yoshinobu Aisa, Takayuki Shimizu, Shinichiro Okamoto

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


We retrospectively evaluated single-institute outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with a reduced-intensity conditioning regimen consisting of fludarabine (125 mg/m2) and melphalan (140 mg/m2) for multiple myeloma. Twenty-three patients (median age: 46 years) were evaluated. Stem cell sources were bone marrow or peripheral blood stem cells from siblings (n = 4) and bone marrow from unrelated donors (n = 19). For graft-versus-host disease prophylaxis, cyclosporine A or tacrolimus with short-term methotrexate was given. Disease status at time of transplant was complete response in four patients, very good partial or partial response in 13, and stable or progressive disease in six. The median follow-up period of 7 survivors at analysis was 73.2 months (range 46.0–158.9 months). During the follow-up, disease recurrence or progression was observed in 21 patients, and was primary causes of death in 88 % of the patients. The 5-year overall survival and progression-free survival rates were 38.6 % (95 % CI 19.3–57.7 %) and 5.4 % (95 % CI 0.4–21.6 %), respectively. Although allo-HSCT with this conditioning could be safely performed, further refinement of this approach aiming at more effective eradication of myeloma cells is clearly warranted.

Original languageEnglish
Pages (from-to)670-677
Number of pages8
JournalInternational journal of hematology
Issue number6
Publication statusPublished - 2015 Dec 1


  • Allogeneic hematopoietic stem cell transplantation
  • Fludarabine
  • Melphalan
  • Multiple myeloma
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma'. Together they form a unique fingerprint.

Cite this